Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Aleve Ads Cite Specific FDA Advisory Panel Opinions On Naproxen Safety

This article was originally published in The Pink Sheet Daily

Executive Summary

Bayer steers clear of directly implying FDA endorsement of naproxen's safety by referencing mainstream media reports on the committees' discussions about COX-2 inhibitors and NSAIDs.

You may also be interested in...

Crestor Safety Defense Misrepresents FDA Position, Agency Tells Company

An AstraZeneca “patient safety” print ad that ran in mid-November “misleadingly suggests that the agency does not believe that Crestor poses safety concerns,” the FDA ad division says in an “untitled” letter to the company. The Crestor ad asserted FDA has concluded safety concerns about rosuvastatin “have no medical or scientific basis.”

NDAC Approach To OTC Switches Highlighted At Corticosteroid Meeting

Panel review provides examples of different attitudes toward switches between OTC experts, other category-specific prescribers.

Plan B Decision Expected In Coming Weeks, Barr CEO Says

Downey says Rx sales of approximately $20 mil. have restricted availability of the emergency contraceptive at pharmacies across the country.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts